Ischemic stroke in anti-β2-glycoprotein I IgA-associated non-criteria antiphospholipid syndrome: a case report of arterial recanalization via antiplatelet therapy

Background The pathogenic potential of non-criteria antiphospholipid antibodies (aPLs), such as anti-β2-glycoprotein I (aβ2GPI) IgA, remains undefined. Additionally, the role of antiplatelet therapy in thrombotic antiphospholipid syndrome (APS) is controversial. Diagnosing APS is challenging when consensus aPLs are negative. Arterial recanalization via antiplatelet therapy in thrombotic APS has not been reported so far. Case presentation A 65-year-old woman presented with acute basilar artery occlusion. Dual antiplatelet therapy (aspirin + clopidogrel) achieved complete arterial recanalization within 11 days. High-Resolution Magnetic Resonance Imaging excluded atherosclerosis, dissection, or arteritis. Cardiac evaluations ruled out cardioembolism. Laboratory tests revealed persistent isolated high-titer aβ2GPI IgA (>150 U/mL) with negative consensus aPLs. Thrombotic workup excluded hereditary or other secondary thrombophilia, supporting a diagnosis of non-criteria APS. Long-term aspirin monotherapy maintained vascular patency and prevented stroke recurrence over 5 years. Conclusion This case highlights the thrombogenic role of aβ2GPI IgA in seronegative APS and demonstrates the potential efficacy of antiplatelet therapy, a strategy not prioritized in current APS guidelines favoring anticoagulation therapy, in reversing arterial occlusion and preventing recurrence in non-criteria APS. It underscores the need to re-evaluate diagnostic criteria and therapeutic strategy for seronegative APS with non-criteria aPLs.

• Publication year

  2025

• Venue

  Frontiers in Immunology

• Publication date

  2025-07-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.3389/fimmu.2025.1603526PMID 40688083PMCID 12271229
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome

  2025cited by this paper
• Antiphospholipid Syndrome: Insights into Molecular Mechanisms and Clinical Manifestations

  2024cited by this paper
• Dilemmas in the Diagnosis and Management of Antiphospholipid Syndrome.

  2024cited by this paper
• Activation of Platelet mTORC2/Akt Pathway by Anti-β2GP1 Antibody Promotes Thrombosis in Antiphospholipid Syndrome

  2023cited by this paper
• Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch

  2023cited by this paper
• Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

  2023cited by this paper
• 2023 ACR/EULAR antiphospholipid syndrome classification criteria

  2023cited by this paper
• Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients

  2023cited by this paper
• Prevalence of Antiphospholipid Antibodies and Association With Incident Cardiovascular Events

  2023cited by this paper
• [Recommendations for management of antiphospholipid syndrome in China].

  2022cited by this paper
• Presence of Extra-Criteria Antiphospholipid Antibodies Is an Independent Risk Factor for Ischemic Stroke

  2021cited by this paper
• The Weight of IgA Anti-β2glycoprotein I in the Antiphospholipid Syndrome Pathogenesis: Closing the Gap of Seronegative Antiphospholipid Syndrome

  2020cited by this paper
• Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management

  2020cited by this paper
• Immune Complexes of Beta-2-Glycoprotein I and IgA Antiphospholipid Antibodies Identify Patients With Elevated Risk of Thrombosis and Early Mortality After Heart Transplantation

  2019cited by this paper
• Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population.

  2019cited by this paper
• EULAR recommendations for the management of antiphospholipid syndrome in adults

  2019cited by this paper
• The IgA Isotype of Anti-β2 Glycoprotein I Antibodies Recognizes Epitopes in Domains 3, 4, and 5 That Are Located in a Lateral Zone of the Molecule (L-Shaped)

  2019cited by this paper
• Antiphospholipid syndrome causing reversible internal carotid artery thrombosis.

  2018cited by this paper
• Antiphospholipid syndrome and IgA anti-beta2-glycoprotein I antibodies: when Cinderella becomes a princess

  2018cited by this paper
• Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy.

  2017cited by this paper
• Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies

  2017cited by this paper
• Value of isolated IgA anti-β2 -glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome.

  2013cited by this paper
• Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies

  2013cited by this paper
• {beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome.

  2010cited by this paper

• No citing papers are available for this paper.